{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:54:09Z","timestamp":1791219249691,"version":"4.1.0"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004366","name":"Tabriz University of Medical Sciences","doi-asserted-by":"publisher","award":["grant number: 66147"],"award-info":[{"award-number":["grant number: 66147"]}],"id":[{"id":"10.13039\/501100004366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s00228-022-03363-6","type":"journal-article","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T06:04:49Z","timestamp":1658815489000},"page":"1567-1587","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Pharmacotherapy of Alzheimer\u2019s disease: an overview of systematic reviews"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0607-4268","authenticated-orcid":false,"given":"Reza","family":"Majidazar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7132-063X","authenticated-orcid":false,"given":"Erfan","family":"Rezazadeh-Gavgani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2872-1072","authenticated-orcid":false,"given":"Saeed","family":"Sadigh-Eteghad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9723-0109","authenticated-orcid":false,"given":"Amirreza","family":"Naseri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,26]]},"reference":[{"key":"3363_CR1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1201\/9780429277276-6","volume":"-","author":"WA Rocca","year":"2019","unstructured":"Rocca WA, Amaducci L (2019) Epidemiology of Alzheimer\u2019s disease. Neuroepidemiology 55\u201396","journal-title":"Neuroepidemiology"},{"issue":"4","key":"3363_CR2","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1177\/1039856218762308","volume":"26","author":"D Eratne","year":"2018","unstructured":"Eratne D, Loi SM, Farrand S, Kelso W, Velakoulis D, Looi JC (2018) Alzheimer\u2019s disease: clinical update on epidemiology, pathophysiology and diagnosis. Australas Psychiatry 26(4):347\u2013357","journal-title":"Australas Psychiatry"},{"key":"3363_CR3","first-page":"146","volume":"64","author":"A Alzheimer","year":"1907","unstructured":"Alzheimer A (1907) \u00dcber eine eigenartige Erkrankung der Hirnrinde Allgemeine Zeitschrift fur Psychiatrie und Psychisch-gerichtliche Medizin. Psychiatry (Edgmont) 64:146\u2013148","journal-title":"Psychiatry (Edgmont)"},{"issue":"4","key":"3363_CR4","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1037\/a0029857","volume":"27","author":"RS Wilson","year":"2012","unstructured":"Wilson RS, Segawa E, Boyle PA, Anagnos SE, Hizel LP, Bennett DA (2012) The natural history of cognitive decline in Alzheimer\u2019s disease. Psychol Aging 27(4):1008\u20131017","journal-title":"Psychol Aging"},{"issue":"4","key":"3363_CR5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/00002093-200210000-00001","volume":"16","author":"WW Barker","year":"2002","unstructured":"Barker WW, Luis CA, Kashuba A, Luis M, Harwood DG, Loewenstein D et al (2002) Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord 16(4):203\u2013212","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"8","key":"3363_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-015746","volume":"7","author":"F Bature","year":"2017","unstructured":"Bature F, Guinn BA, Pang D, Pappas Y (2017) Signs and symptoms preceding the diagnosis of Alzheimer\u2019s disease: a systematic scoping review of literature from 1937 to 2016. BMJ Open 7(8):e015746","journal-title":"BMJ Open"},{"issue":"72\u201376","key":"3363_CR7","first-page":"92","volume":"157","author":"A Burns","year":"1990","unstructured":"Burns A, Jacoby R, Levy R (1990) Psychiatric phenomena in Alzheimer\u2019s disease. I: Disorders of thought content. Br J Psychiatry 157(72\u201376):92\u201394","journal-title":"Br J Psychiatry"},{"key":"3363_CR8","doi-asserted-by":"crossref","unstructured":"Joe E, Ringman JM (2019) Cognitive symptoms of Alzheimer\u2019s disease: clinical management and prevention. Bmj 367","DOI":"10.1136\/bmj.l6217"},{"issue":"2","key":"3363_CR9","first-page":"263","volume":"103","author":"A Atri","year":"2019","unstructured":"Atri A (2019) The Alzheimer\u2019s disease clinical spectrum: Diagnosis and management. Medical Clinics 103(2):263\u2013293","journal-title":"Medical Clinics"},{"issue":"6 suppl 3","key":"3363_CR10","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1212\/WNL.65.6_suppl_3.S10","volume":"65","author":"HH Feldman","year":"2005","unstructured":"Feldman HH, Woodward M (2005) The staging and assessment of moderate to severe Alzheimer disease. Neurology 65(6 suppl 3):S10","journal-title":"Neurology"},{"issue":"4","key":"3363_CR11","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1002\/alz.12213","volume":"17","author":"DS Knopman","year":"2021","unstructured":"Knopman DS, Jones DT, Greicius MD (2021) Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Alzheimers Dement 17(4):696\u2013701","journal-title":"Alzheimers Dement"},{"issue":"7","key":"3363_CR12","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41582-019-0205-1","volume":"15","author":"DJ Selkoe","year":"2019","unstructured":"Selkoe DJ (2019) Alzheimer disease and aducanumab: adjusting our approach. Nat Rev Neurol 15(7):365\u2013366","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"3363_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.31117\/neuroscirn.v4i2.81","volume":"4","author":"T Retinasamy","year":"2021","unstructured":"Retinasamy T, Shaikh MF (2021) Aducanumab for Alzheimer\u2019s disease: An update. Neurosci Res Notes 4(2):17\u201320","journal-title":"Neurosci Res Notes"},{"key":"3363_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2020.113409","volume":"293","author":"MM Koola","year":"2020","unstructured":"Koola MM (2020) Galantamine-Memantine combination in the treatment of Alzheimer\u2019s disease and beyond. Psychiatry Res 293:113409","journal-title":"Psychiatry Res"},{"key":"3363_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1682","volume":"374","author":"S Walsh","year":"2021","unstructured":"Walsh S, Merrick R, Milne R, Brayne C (2021) Aducanumab for Alzheimer\u2019s disease? BMJ 374:n1682","journal-title":"BMJ"},{"key":"3363_CR16","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1016\/j.biopha.2018.11.115","volume":"109","author":"M Hassan","year":"2019","unstructured":"Hassan M, Raza H, Abbasi MA, Moustafa AA, Seo S-Y (2019) The exploration of novel Alzheimer\u2019s therapeutic agents from the pool of FDA approved medicines using drug repositioning, enzyme inhibition and kinetic mechanism approaches. Biomed Pharmacother 109:2513\u20132526","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"3363_CR17","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s40266-017-0499-x","volume":"34","author":"R Khoury","year":"2017","unstructured":"Khoury R, Patel K, Gold J, Hinds S, Grossberg GT (2017) Recent progress in the pharmacotherapy of Alzheimer\u2019s disease. Drugs Aging 34(11):811\u2013820","journal-title":"Drugs Aging"},{"issue":"8","key":"3363_CR18","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/gps.4405","volume":"31","author":"H Kobayashi","year":"2016","unstructured":"Kobayashi H, Ohnishi T, Nakagawa R, Yoshizawa K (2016) The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer\u2019s disease: a Bayesian network meta-analysis. Int J Geriatr Psychiatry 31(8):892\u2013904","journal-title":"Int J Geriatr Psychiatry"},{"issue":"1","key":"3363_CR19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/cpt.1104","volume":"105","author":"KK Tsoi","year":"2019","unstructured":"Tsoi KK, Chan JY, Chan FC, Hirai HW, Kwok TC, Wong SY (2019) Monotherapy is good enough for patients with mild-to-moderate Alzheimer\u2019s disease: a network meta-analysis of 76 randomized controlled trials. Clin Pharmacol Ther 105(1):121\u2013130","journal-title":"Clin Pharmacol Ther"},{"issue":"27","key":"3363_CR20","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016091","volume":"98","author":"CC Cui","year":"2019","unstructured":"Cui CC, Sun Y, Wang XY, Zhang Y, Xing Y (2019) The effect of anti-dementia drugs on Alzheimer disease-induced cognitive impairment: A network meta-analysis. Medicine (Baltimore) 98(27):e16091","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"3363_CR21","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.3233\/JAD-215423","volume":"85","author":"F Fan","year":"2022","unstructured":"Fan F, Liu H, Shi X, Ai Y, Liu Q, Cheng Y (2022) The efficacy and safety of Alzheimer\u2019s disease therapies: An updated umbrella review. J Alzheimers Dis 85(3):1195\u20131204","journal-title":"J Alzheimers Dis"},{"key":"3363_CR22","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jclinepi.2015.06.005","volume":"69","author":"P Whiting","year":"2016","unstructured":"Whiting P, Savovi\u0107 J, Higgins JP, Caldwell DM, Reeves BC, Shea B et al (2016) ROBIS: a new tool to assess risk of bias in systematic reviews was developed. J Clin Epidemiol 69:225\u2013234","journal-title":"J Clin Epidemiol"},{"key":"3363_CR23","doi-asserted-by":"crossref","unstructured":"Kurlowicz L, Wallace M (1999) The mini-mental state examination (MMSE). SLACK Incorporated Thorofare, NJ\u00a08\u20139","DOI":"10.3928\/0098-9134-19990501-08"},{"issue":"3","key":"3363_CR24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR (1975) \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189\u201398","journal-title":"J Psychiatr Res"},{"issue":"2","key":"3363_CR25","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3233\/JAD-170991","volume":"63","author":"JK Kueper","year":"2018","unstructured":"Kueper JK, Speechley M, Montero-Odasso M (2018) The Alzheimer\u2019s disease assessment scale-cognitive subscale (ADAS-Cog): Modifications and responsiveness in pre-dementia populations. A narrative review. J Alzheimers Dis 63(2):423\u2013444","journal-title":"J Alzheimers Dis"},{"key":"3363_CR26","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/B978-072160361-2.50020-X","volume-title":"Physical Rehabilitation","author":"L Quinn","year":"2007","unstructured":"Quinn L, Bello-Haas VD (2007) Chapter 17 - Progressive Central Nervous System Disorders. In: Cameron MH, Monroe LG (eds) Physical Rehabilitation. W.B. Saunders, Saint Louis, pp 436\u2013472"},{"issue":"8","key":"3363_CR27","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1001\/archneur.65.8.1091","volume":"65","author":"SE O'Bryant","year":"2008","unstructured":"O\u2019Bryant SE, Waring SC, Cullum CM, Hall J, Lacritz L, Massman PJ et al (2008) Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer\u2019s research consortium study. Arch Neurol 65(8):1091\u20131095","journal-title":"Arch Neurol"},{"key":"3363_CR28","doi-asserted-by":"crossref","unstructured":"Khan TK (2016) Chapter 2 - Clinical Diagnosis of Alzheimer\u2019s Disease. In Khan TK, editor. Biomarkers in Alzheimer's Disease: Academic Press\u00a027\u201348","DOI":"10.1016\/B978-0-12-804832-0.00002-X"},{"issue":"1","key":"3363_CR29","doi-asserted-by":"publisher","first-page":"E53","DOI":"10.25011\/cim.v42i1.32393","volume":"42","author":"N Foroutan","year":"2019","unstructured":"Foroutan N, Hopkins RB, Tarride JE, Florez ID, Levine M (2019) Safety and efficacy of active and passive immunotherapy in mild-to-moderate Alzheimer\u2019s disease: A systematic review and network meta-analysis. Clin Invest Med 42(1):E53\u2013E65","journal-title":"Clin Invest Med"},{"issue":"4","key":"3363_CR30","first-page":"83","volume":"62","author":"C Li","year":"2016","unstructured":"Li C, Ma Q, Chen S, Feng J, He Y (2016) Amyloid beta directed antibody for Alzheimer\u2019s disease, an evidence based meta-analysis. Cell Mol Biol (Noisy-le-grand) 62(4):83\u201387","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"issue":"12","key":"3363_CR31","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1136\/jnnp-2020-323497","volume":"91","author":"L Lu","year":"2020","unstructured":"Lu L, Zheng X, Wang S, Tang C, Zhang Y, Yao G et al (2020) Anti-A\u03b2 agents for mild to moderate Alzheimer\u2019s disease: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 91(12):1316\u20131324","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"3363_CR32","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s11481-016-9722-5","volume":"12","author":"R Penninkilampi","year":"2017","unstructured":"Penninkilampi R, Brothers HM, Eslick GD (2017) Safety and efficacy of anti-amyloid-\u03b2 immunotherapy in Alzheimer\u2019s disease: A systematic review and meta-analysis. J Neuroimmune Pharmacol 12(1):194\u2013203","journal-title":"J Neuroimmune Pharmacol"},{"key":"3363_CR33","doi-asserted-by":"crossref","unstructured":"Abushouk AI, Elmaraezy A, Aglan A, Salama R, Fouda S, Fouda R et al (2017) Bapineuzumab for mild to moderate Alzheimer's disease: A meta-analysis of randomized controlled trials. BMC Neurol 17(1)","DOI":"10.1186\/s12883-017-0850-1"},{"issue":"6","key":"3363_CR34","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1080\/14737175.2019.1620106","volume":"19","author":"J Liu","year":"2019","unstructured":"Liu J, Wang LN (2019) Intravenous immunoglobulins for Alzheimer\u2019s disease and mild cognitive impairment due to Alzheimer\u2019s disease: A systematic review with meta-analysis. Expert Rev Neurother 19(6):475\u2013480","journal-title":"Expert Rev Neurother"},{"issue":"5","key":"3363_CR35","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1177\/1533317519843720","volume":"34","author":"A Manolopoulos","year":"2019","unstructured":"Manolopoulos A, Andreadis P, Malandris K, Avgerinos I, Karagiannis T, Kapogiannis D et al (2019) Intravenous Immunoglobulin for patients with Alzheimer\u2019s disease: A systematic review and meta-analysis. Am J Alzheimers Dis Other Demen 34(5):281\u2013289","journal-title":"Am J Alzheimers Dis Other Demen"},{"issue":"4","key":"3363_CR36","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.3233\/JAD-180888","volume":"66","author":"M Okuya","year":"2018","unstructured":"Okuya M, Matsunaga S, Ikuta T, Kishi T, Iwata N (2018) Efficacy, acceptability, and safety of intravenous immunoglobulin administration for mild-to-moderate Alzheimer\u2019s disease: A systematic review and meta-analysis. J Alzheimers Dis 66(4):1379\u20131387","journal-title":"J Alzheimers Dis"},{"issue":"7","key":"3363_CR37","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/ijnp\/pyx012","volume":"20","author":"L Blanco-Silvente","year":"2017","unstructured":"Blanco-Silvente L, Castells X, Saez M, Barcel\u00f3 MA, Garre-Olmo J, Vilalta-Franch J et al (2017) Discontinuation, efficacy, and safety of cholinesterase inhibitors for Alzheimer\u2019s disease: a meta-analysis and meta-regression of 43 randomized clinical trials enrolling 16 106 patients. Int J Neuropsychopharmacol 20(7):519\u2013528","journal-title":"Int J Neuropsychopharmacol"},{"issue":"9","key":"3363_CR38","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1586\/14737175.2015.1068120","volume":"15","author":"J Su","year":"2015","unstructured":"Su J, Liu Y, Liu Y, Ren L (2015) Long-term effectiveness of rivastigmine patch or capsule for mild-to-severe Alzheimers disease: A meta-analysis. Expert Rev Neurother 15(9):1093\u20131103","journal-title":"Expert Rev Neurother"},{"key":"3363_CR39","doi-asserted-by":"crossref","unstructured":"Birks JS, Evans JG (2015) Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev (4):Cd001191","DOI":"10.1002\/14651858.CD001191.pub3"},{"issue":"8","key":"3363_CR40","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s00702-014-1358-0","volume":"122","author":"D Jiang","year":"2015","unstructured":"Jiang D, Yang X, Li M, Wang Y, Wang Y (2015) Efficacy and safety of galantamine treatment for patients with Alzheimer\u2019s disease: a meta-analysis of randomized controlled trials. J Neural Transm (Vienna) 122(8):1157\u20131166","journal-title":"J Neural Transm (Vienna)"},{"issue":"4","key":"3363_CR41","first-page":"7423","volume":"9","author":"X Zhang","year":"2016","unstructured":"Zhang X, Shao J, Wei Y, Zhang H (2016) Efficacy of galantamine in treatment of Alzheimer\u2019s disease: an update meta-analysis. Int J Clin Exp Med 9(4):7423\u20137430","journal-title":"Int J Clin Exp Med"},{"key":"3363_CR42","doi-asserted-by":"crossref","unstructured":"Li D-D, Zhang Y-H, Zhang W, Zhao P (2019) Meta-analysis of randomized controlled trials on the efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer\u2019s disease. Front Neurosci 13(472)","DOI":"10.3389\/fnins.2019.00472"},{"issue":"1","key":"3363_CR43","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s12877-018-0857-5","volume":"18","author":"L Blanco-Silvente","year":"2018","unstructured":"Blanco-Silvente L, Capell\u00e0 D, Garre-Olmo J, Vilalta-Franch J, Castells X (2018) Predictors of discontinuation, efficacy, and safety of memantine treatment for Alzheimer\u2019s disease: meta-analysis and meta-regression of 18 randomized clinical trials involving 5004 patients. BMC Geriatr 18(1):168","journal-title":"BMC Geriatr"},{"issue":"9","key":"3363_CR44","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s10072-015-2221-2","volume":"36","author":"J Jiang","year":"2015","unstructured":"Jiang J, Jiang H (2015) Efficacy and adverse effects of memantine treatment for Alzheimer\u2019s disease from randomized controlled trials. Neurol Sci 36(9):1633\u20131641","journal-title":"Neurol Sci"},{"issue":"2","key":"3363_CR45","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3233\/JAD-170424","volume":"60","author":"T Kishi","year":"2017","unstructured":"Kishi T, Matsunaga S, Oya K, Nomura I, Ikuta T, Iwata N (2017) Memantine for Alzheimer\u2019s disease: An updated systematic review and meta-analysis. J Alzheimers Dis 60(2):401\u2013425","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"3363_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123289","volume":"10","author":"S Matsunaga","year":"2015","unstructured":"Matsunaga S, Kishi T, Iwata N (2015) Memantine monotherapy for Alzheimer\u2019s disease: a systematic review and meta-analysis. PLoS ONE 10(4):e0123289","journal-title":"PLoS ONE"},{"key":"3363_CR47","doi-asserted-by":"crossref","unstructured":"McShane R, Westby MJ, Roberts E, Minakaran N, Schneider L, Farrimond LE et al (2019) Memantine for dementia. Cochrane Database Syst Rev (3)","DOI":"10.1002\/14651858.CD003154.pub6"},{"key":"3363_CR48","doi-asserted-by":"crossref","unstructured":"Sumsuzzman DM, Choi J, Jin Y, Hong Y (2021) Neurocognitive effects of melatonin treatment in healthy adults and individuals with Alzheimer\u2019s disease and insomnia: a systematic review and meta-analysis of randomized controlled trials. Neurosci Biobehav Rev","DOI":"10.1016\/j.neubiorev.2021.04.034"},{"issue":"1","key":"3363_CR49","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/gps.4571","volume":"32","author":"Y-Y Wang","year":"2017","unstructured":"Wang Y-Y, Zheng W, Ng CH, Ungvari GS, Wei W, Xiang Y-T (2017) Meta-analysis of randomized, double-blind, placebo-controlled trials of melatonin in Alzheimer\u2019s disease. Int J Geriatr Psychiatry 32(1):50\u201357","journal-title":"Int J Geriatr Psychiatry"},{"issue":"6","key":"3363_CR50","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s10072-020-04243-6","volume":"41","author":"K Xuan","year":"2020","unstructured":"Xuan K, Zhao T, Qu G, Liu H, Chen X, Sun Y (2020) The efficacy of statins in the treatment of Alzheimer\u2019s disease: a meta-analysis of randomized controlled trial. Neurol Sci 41(6):1391\u20131404","journal-title":"Neurol Sci"},{"issue":"6","key":"3363_CR51","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/ijcp.12626","volume":"69","author":"R Ye","year":"2015","unstructured":"Ye R, Hu Y, Yao A, Yang Y, Shi Y, Jiang Y et al (2015) Impact of renin\u2013angiotensin system-targeting antihypertensive drugs on treatment of Alzheimer\u2019s disease: a meta-analysis. Int J Clin Pract 69(6):674\u2013681","journal-title":"Int J Clin Pract"},{"issue":"2","key":"3363_CR52","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s40266-015-0239-z","volume":"32","author":"M Miguel-\u00c1lvarez","year":"2015","unstructured":"Miguel-\u00c1lvarez M, Santos-Lozano A, Sanchis-Gomar F, Fiuza-Luces C, Pareja-Galeano H, Garatachea N et al (2015) Non-steroidal anti-inflammatory drugs as a treatment for Alzheimer\u2019s disease: A systematic review and meta-analysis of treatment effect. Drugs Aging 32(2):139\u2013147","journal-title":"Drugs Aging"},{"issue":"10","key":"3363_CR53","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1111\/dom.13373","volume":"20","author":"B Cao","year":"2018","unstructured":"Cao B, Rosenblat JD, Brietzke E, Park C, Lee Y, Musial N et al (2018) Comparative efficacy and acceptability of antidiabetic agents for Alzheimer\u2019s disease and mild cognitive impairment: A systematic review and network meta-analysis. Diabetes Obes Metab 20(10):2467\u20132471","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"3363_CR54","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3233\/JAD-150437","volume":"48","author":"S Matsunaga","year":"2015","unstructured":"Matsunaga S, Kishi T, Annas P, Basun H, Hampel H, Iwata N (2015) Lithium as a treatment for Alzheimer\u2019s disease: a systematic review and meta-analysis. J Alzheimers Dis 48(2):403\u2013410","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"3363_CR55","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.3233\/JAD-190256","volume":"69","author":"S Matsunaga","year":"2019","unstructured":"Matsunaga S, Fujishiro H, Takechi H (2019) Efficacy and safety of glycogen synthase kinase 3 inhibitors for Alzheimer\u2019s disease: A systematic review and meta-analysis. J Alzheimers Dis 69(4):1031\u20131039","journal-title":"J Alzheimers Dis"},{"issue":"5\u20136","key":"3363_CR56","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1159\/000377672","volume":"39","author":"S Gauthier","year":"2015","unstructured":"Gauthier S, Proa\u00f1o JV, Jia J, Froelich L, Vester JC, Doppler E (2015) Cerebrolysin in mild-to-moderate Alzheimer\u2019s disease: A meta-analysis of randomized controlled clinical trials. Dement Geriatr Cogn Disord 39(5\u20136):332\u2013347","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"3","key":"3363_CR57","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1055\/a-1076-8228","volume":"53","author":"T Kishi","year":"2020","unstructured":"Kishi T, Sakuma K, Iwata N (2020) Efficacy and safety of psychostimulants for Alzheimer\u2019s disease: A systematic review and meta-analysis. Pharmacopsychiatry 53(3):109\u2013114","journal-title":"Pharmacopsychiatry"},{"issue":"4","key":"3363_CR58","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000018507","volume":"99","author":"Y Kim","year":"2020","unstructured":"Kim Y, Cho SH (2020) Danggui-Shaoyao-San for dementia: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore) 99(4):e18507","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"3363_CR59","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/WNF.0000000000000394","volume":"43","author":"Z Liao","year":"2020","unstructured":"Liao Z, Cheng L, Li X, Zhang M, Wang S, Huo R (2020) Meta-analysis of Ginkgo biloba preparation for the treatment of Alzheimer\u2019s disease. Clin Neuropharmacol 43(4):93\u201399","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"3363_CR60","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.imr.2019.04.006","volume":"8","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Noh K, Song W (2019) Chinese herbal medicines on cognitive function and activity of daily living in senior adults with Alzheimer\u2019s disease: a systematic review and meta-analysis. Integr Med Res 8(2):92\u2013100","journal-title":"Integr Med Res"},{"issue":"3","key":"3363_CR61","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR (1975) \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr res 12(3):189\u201398","journal-title":"J Psychiatr res"},{"issue":"11","key":"3363_CR62","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","volume":"141","author":"WG Rosen","year":"1984","unstructured":"Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer\u2019s disease. Am J Psychiatry 141(11):1356\u20131364","journal-title":"Am J Psychiatry"},{"issue":"2","key":"3363_CR63","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/ebmental-2020-300184","volume":"24","author":"SZ Levine","year":"2021","unstructured":"Levine SZ, Yoshida K, Goldberg Y, Samara M, Cipriani A, Efthimiou O et al (2021) Linking the mini-mental state examination, the Alzheimer\u2019s disease assessment scale-cognitive subscale and the severe impairment battery: evidence from individual participant data from five randomised clinical trials of donepezil. Evidence Based Mental Health 24(2):56","journal-title":"Evidence Based Mental Health"},{"issue":"7","key":"3363_CR64","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1080\/13854046.2015.1119312","volume":"29","author":"S Balsis","year":"2015","unstructured":"Balsis S, Benge JF, Lowe DA, Geraci L, Doody RS (2015) How do scores on the ADAS-Cog, MMSE, and CDR-SOB correspond? Clin Neuropsychol 29(7):1002\u20131009","journal-title":"Clin Neuropsychol"},{"key":"3363_CR65","doi-asserted-by":"crossref","unstructured":"Khandker R, Black C, Pike J, Husbands J, Ambegaonkar B, Jones E (2018) The relationship between mini-mental state examination (MMSE) & Alzheimer\u2019s disease assessment scale-cognitive subscale (ADAS-cog) using real world data in US & Europe (P5.178). Neurology 90(15 Supplement):P5.178","DOI":"10.1212\/WNL.90.15_supplement.P5.178"},{"issue":"S9","key":"3363_CR66","doi-asserted-by":"publisher","DOI":"10.1002\/alz.052153","volume":"17","author":"E Mitchell","year":"2021","unstructured":"Mitchell E, d\u2019Amico V, Geerts H (2021) Relationship between CDR Sum of Boxes and ADAS-COG derived from historical clinical trials. Alzheimers Dement 17(S9):e052153","journal-title":"Alzheimers Dement"},{"issue":"6","key":"3363_CR67","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1177\/1756285612455733","volume":"5","author":"B Sheehan","year":"2012","unstructured":"Sheehan B (2012) Assessment scales in dementia. Ther Adv Neurol Disord 5(6):349\u2013358","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"3363_CR68","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/ana.410300410","volume":"30","author":"RD Terry","year":"1991","unstructured":"Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R et al (1991) Physical basis of cognitive alterations in Alzheimer\u2019s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30(4):572\u2013580","journal-title":"Ann Neurol"},{"issue":"1","key":"3363_CR69","doi-asserted-by":"publisher","first-page":"6555","DOI":"10.1038\/s41598-019-43076-y","volume":"9","author":"G Kashyap","year":"2019","unstructured":"Kashyap G, Bapat D, Das D, Gowaikar R, Amritkar RE, Rangarajan G et al (2019) Synapse loss and progress of Alzheimer\u2019s disease -A network model. Sci Rep 9(1):6555","journal-title":"Sci Rep"},{"issue":"2","key":"3363_CR70","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/BF00697388","volume":"61","author":"T Arendt","year":"1983","unstructured":"Arendt T, Bigl V, Arendt A, Tennstedt A (1983) Loss of neurons in the nucleus basalis of Meynert in Alzheimer\u2019s disease, paralysis agitans and Korsakoff\u2019s Disease. Acta Neuropathol 61(2):101\u2013108","journal-title":"Acta Neuropathol"},{"issue":"8","key":"3363_CR71","first-page":"1161","volume":"117","author":"JP Jia","year":"2004","unstructured":"Jia JP, Jia JM, Zhou WD, Xu M, Chu CB, Yan X et al (2004) Differential acetylcholine and choline concentrations in the cerebrospinal fluid of patients with Alzheimer\u2019s disease and vascular dementia. Chin Med J 117(8):1161\u20131164","journal-title":"Chin Med J"},{"issue":"1","key":"3363_CR72","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3233\/JAD-2007-11113","volume":"11","author":"CP Jacob","year":"2007","unstructured":"Jacob CP, Koutsilieri E, Bartl J, Neuen-Jacob E, Arzberger T, Zander N et al (2007) Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer\u2019s disease. J Alzheimes Dis JAD 11(1):97\u2013116","journal-title":"J Alzheimes Dis JAD"},{"issue":"7433","key":"3363_CR73","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature11775","volume":"493","author":"AJ Granger","year":"2013","unstructured":"Granger AJ, Shi Y, Lu W, Cerpas M, Nicoll RA (2013) LTP requires a reserve pool of glutamate receptors independent of subunit type. Nature 493(7433):495\u2013500","journal-title":"Nature"},{"issue":"11","key":"3363_CR74","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1038\/npp.2014.119","volume":"39","author":"G Koch","year":"2014","unstructured":"Koch G, Di Lorenzo F, Bonn\u00ec S, Giacobbe V, Bozzali M, Caltagirone C et al (2014) Dopaminergic modulation of cortical plasticity in Alzheimer\u2019s disease patients. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 39(11):2654\u20132661","journal-title":"Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology"},{"issue":"-","key":"3363_CR75","doi-asserted-by":"crossref","first-page":"239821281985824","DOI":"10.1177\/2398212819858249","volume":"3","author":"TG Smart","year":"2019","unstructured":"Smart TG, Stephenson FA (2019) A half century of \u03b3-aminobutyric acid. Brain Neurosci Adv 3:2398212819858249","journal-title":"Brain Neurosci Adv"},{"issue":"3","key":"3363_CR76","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1124\/jpet.102.041616","volume":"306","author":"AV Terry Jr","year":"2003","unstructured":"Terry AV Jr, Buccafusco JJ (2003) The cholinergic hypothesis of age and Alzheimer\u2019s disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 306(3):821\u2013827","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"3363_CR77","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/0753-3322(89)90109-1","volume":"43","author":"F Boller","year":"1989","unstructured":"Boller F, Forette F (1989) Alzheimer\u2019s disease and THA: a review of the cholinergic theory and of preliminary results. Biomed Pharmacother 43(7):487\u2013491","journal-title":"Biomed Pharmacother"},{"issue":"7179","key":"3363_CR78","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/nature06616","volume":"451","author":"M Meyer-Luehmann","year":"2008","unstructured":"Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A et al (2008) Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer\u2019s disease. Nature 451(7179):720\u2013724","journal-title":"Nature"},{"issue":"6","key":"3363_CR79","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nsmb.2991","volume":"22","author":"Y Xiao","year":"2015","unstructured":"Xiao Y, Ma B, McElheny D, Parthasarathy S, Long F, Hoshi M et al (2015) A\u03b2(1\u201342) fibril structure illuminates self-recognition and replication of amyloid in Alzheimer\u2019s disease. Nat Struct Mol Biol 22(6):499\u2013505","journal-title":"Nat Struct Mol Biol"},{"issue":"1","key":"3363_CR80","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.arr.2012.06.003","volume":"12","author":"L Martin","year":"2013","unstructured":"Martin L, Latypova X, Wilson CM, Magnaudeix A, Perrin ML, Yardin C et al (2013) Tau protein kinases: involvement in Alzheimer\u2019s disease. Ageing Res Rev 12(1):289\u2013309","journal-title":"Ageing Res Rev"},{"issue":"1","key":"3363_CR81","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00401-015-1507-z","volume":"131","author":"J Lewis","year":"2016","unstructured":"Lewis J, Dickson DW (2016) Propagation of tau pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol 131(1):27\u201348","journal-title":"Acta Neuropathol"},{"issue":"9","key":"3363_CR82","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.3390\/ijms21093165","volume":"21","author":"TT Nguyen","year":"2020","unstructured":"Nguyen TT, Ta QTH, Nguyen TKO, Nguyen TTD, Giau VV (2020) Type 3 diabetes and its role implications in Alzheimer\u2019s disease. Int J Mol Sci 21(9):3165","journal-title":"Int J Mol Sci"},{"issue":"-","key":"3363_CR83","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3389\/fnagi.2018.00083","volume":"10","author":"C Zhang","year":"2018","unstructured":"Zhang C, Wang Y, Wang D, Zhang J, Zhang F (2018) NSAID exposure and risk of Alzheimer\u2019s disease: An updated meta-analysis from cohort studies. Front Aging Neurosci 10:83","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"3363_CR84","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3233\/JAD-180288","volume":"64","author":"SC Larsson","year":"2018","unstructured":"Larsson SC, Markus HS (2018) Does treating vascular risk factors prevent dementia and Alzheimer\u2019s disease? a systematic review and meta-analysis. J Alzheimers Dis JAD 64(2):657\u2013668","journal-title":"J Alzheimers Dis JAD"},{"key":"3363_CR85","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.trci.2019.05.008","volume":"5","author":"J Cummings","year":"2019","unstructured":"Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K (2019) Alzheimer\u2019s disease drug development pipeline: 2019. Alzheimers Dement Transl Res Clin Interv 5:272\u2013293","journal-title":"Alzheimers Dement Transl Res Clin Interv"},{"issue":"1","key":"3363_CR86","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13024-021-00424-9","volume":"16","author":"J Cummings","year":"2021","unstructured":"Cummings J (2021) New approaches to symptomatic treatments for Alzheimer\u2019s disease. Mol Neurodegener 16(1):2","journal-title":"Mol Neurodegener"},{"issue":"5","key":"3363_CR87","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3892\/br.2016.630","volume":"4","author":"W-J Huang","year":"2016","unstructured":"Huang W-J, Zhang X, Chen W-W (2016) Role of oxidative stress in Alzheimer\u2019s disease. Biomed Rep 4(5):519\u2013522","journal-title":"Biomed Rep"},{"key":"3363_CR88","doi-asserted-by":"crossref","unstructured":"Lee J, Jin C, Cho S-Y, Park S-U, Jung W-S, Moon S-K et al (2020) Herbal medicine treatment for Alzheimer disease: A protocol for a systematic review and meta-analysis. Medicine 99(33)","DOI":"10.1097\/MD.0000000000021745"},{"issue":"6","key":"3363_CR89","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.ctim.2015.06.009","volume":"23","author":"H Tajadini","year":"2015","unstructured":"Tajadini H, Saifadini R, Choopani R, Mehrabani M, Kamalinejad M, Haghdoost AA (2015) Herbal medicine Davaie Loban in mild to moderate Alzheimer\u2019s disease: A 12-week randomized double-blind placebo-controlled clinical trial. Complement Ther Med 23(6):767\u2013772","journal-title":"Complement Ther Med"},{"issue":"5","key":"3363_CR90","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/alzrt54","volume":"2","author":"J Tian","year":"2010","unstructured":"Tian J, Shi J, Zhang X, Wang Y (2010) Herbal therapy: a new pathway for the treatment of Alzheimer\u2019s disease. Alzheimers Res Ther 2(5):30","journal-title":"Alzheimers Res Ther"},{"key":"3363_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.prmcm.2021.100030","volume":"2","author":"OO John","year":"2022","unstructured":"John OO, Amarachi IS, Chinazom AP, Adaeze E, Kale MB, Umare MD et al (2022) Phytotherapy: A promising approach for the treatment of Alzheimer\u2019s disease. Pharmacol Res Modern Chin Med 2:100030","journal-title":"Pharmacol Res Modern Chin Med"},{"key":"3363_CR92","doi-asserted-by":"crossref","unstructured":"Santos-Neto LLD, de Vilhena Toledo MA, Medeiros-Souza P, de Souza GA (2006) The use of herbal medicine in Alzheimer's disease\u2014A systematic review. Evid Based Complementary Altern Med 3:429564","DOI":"10.1093\/ecam\/nel071"},{"issue":"4","key":"3363_CR93","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.3233\/JAD-180903","volume":"67","author":"GT Grossberg","year":"2019","unstructured":"Grossberg GT, Tong G, Burke AD, Tariot PN (2019) Present algorithms and future treatments for Alzheimer\u2019s disease. J Alzheimers Dis 67(4):1157\u20131171","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"3363_CR94","doi-asserted-by":"publisher","first-page":"725","DOI":"10.3233\/JAD-200378","volume":"76","author":"BLC Piamonte","year":"2020","unstructured":"Piamonte BLC, Espiritu AI, Anlacan VMM (2020) Effects of citicoline as an adjunct treatment for Alzheimer\u2019s disease: a systematic review. J Alzheimers Dis 76(2):725\u2013732","journal-title":"J Alzheimers Dis"},{"issue":"11","key":"3363_CR95","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.2165\/00003495-200666110-00015","volume":"66","author":"DM Robinson","year":"2006","unstructured":"Robinson DM, Keating GM (2006) Memantine: a review of its use in Alzheimer\u2019s disease. Drugs 66(11):1515\u20131534","journal-title":"Drugs"},{"key":"3363_CR96","doi-asserted-by":"crossref","unstructured":"Matsunaga S, Kishi T, Iwata N (2014) Combination therapy with cholinesterase inhibitors and memantine for Alzheimer's disease: a systematic review and meta-analysis. Int J Neuropsychopharmacol 18(5)","DOI":"10.1093\/ijnp\/pyu115"},{"key":"3363_CR97","volume":"149","author":"D Glinz","year":"2019","unstructured":"Glinz D, Gloy VL, Monsch AU, Kressig RW, Patel C, McCord KA et al (2019) Acetylcholinesterase inhibitors combined with memantine for moderate to severe Alzheimer\u2019s disease: a meta-analysis. Swiss Med Wkly 149:w20093","journal-title":"Swiss Med Wkly"},{"issue":"11","key":"3363_CR98","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1831","volume":"10","author":"J Guo","year":"2020","unstructured":"Guo J, Wang Z, Liu R, Huang Y, Zhang N, Zhang R (2020) Memantine, donepezil, or combination therapy\u2014what is the best therapy for Alzheimer\u2019s disease? A network meta-analysis. Brain Behav 10(11):e01831","journal-title":"Brain Behav"},{"issue":"Suppl 1","key":"3363_CR99","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/cei.12500","volume":"178","author":"N Relkin","year":"2014","unstructured":"Relkin N (2014) Intravenous immunoglobulin for Alzheimer\u2019s disease. Clin Exp Immunol 178(Suppl 1):27\u20139","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"3363_CR100","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.biopsych.2017.08.010","volume":"83","author":"CH van Dyck","year":"2018","unstructured":"van Dyck CH (2018) Anti-amyloid-\u03b2 monoclonal antibodies for Alzheimer\u2019s disease: Pitfalls and Promise. Biol Psychiat 83(4):311\u2013319","journal-title":"Biol Psychiat"},{"issue":"3","key":"3363_CR101","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S1474-4422(13)70015-2","volume":"12","author":"C Holmes","year":"2013","unstructured":"Holmes C (2013) Intravenous immunoglobulin for Alzheimer\u2019s disease. Lancet Neurol 12(3):218\u2013219","journal-title":"Lancet Neurol"},{"issue":"1","key":"3363_CR102","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13195-021-00788-6","volume":"13","author":"A Nous","year":"2021","unstructured":"Nous A, Engelborghs S, Smolders I (2021) Melatonin levels in the Alzheimer\u2019s disease continuum: a systematic review. Alzheimers Res Ther 13(1):52","journal-title":"Alzheimers Res Ther"},{"issue":"6","key":"3363_CR103","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0065232","volume":"8","author":"J Wang","year":"2013","unstructured":"Wang J, Zhao Z, Lin E, Zhao W, Qian X, Freire D et al (2013) Unintended effects of cardiovascular drugs on the pathogenesis of Alzheimer\u2019s disease. PLoS ONE 8(6):e65232","journal-title":"PLoS ONE"},{"issue":"1","key":"3363_CR104","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12108","volume":"6","author":"G Torrandell-Haro","year":"2020","unstructured":"Torrandell-Haro G, Branigan GL, Vitali F, Geifman N, Zissimopoulos JM, Brinton RD (2020) Statin therapy and risk of Alzheimer\u2019s and age-related neurodegenerative diseases. Alzheimers Dement Transl Res Clin Interv 6(1):e12108","journal-title":"Alzheimer's Dement Transl Res Clin Interv"},{"issue":"1","key":"3363_CR105","doi-asserted-by":"publisher","first-page":"15280","DOI":"10.1038\/s41598-021-94803-3","volume":"11","author":"S-M Jeong","year":"2021","unstructured":"Jeong S-M, Shin DW, Yoo TG, Cho MH, Jang W, Lee J et al (2021) Association between statin use and Alzheimer\u2019s disease with dose response relationship. Sci Rep 11(1):15280","journal-title":"Sci Rep"},{"key":"3363_CR106","doi-asserted-by":"crossref","unstructured":"Ant\u00f3n \u00c1lvarez X, Fuentes P (2011) Cerebrolysin in Alzheimer's disease. Drugs Today (Barcelona, Spain: 1998) 47(7):487\u2013513","DOI":"10.1358\/dot.2011.47.7.1656496"},{"issue":"5","key":"3363_CR107","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1002\/med.21722","volume":"41","author":"SI Gavrilova","year":"2021","unstructured":"Gavrilova SI, Alvarez A (2021) Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer\u2019s disease: 30 years of clinical use. Med Res Rev 41(5):2775\u20132803","journal-title":"Med Res Rev"},{"issue":"5","key":"3363_CR108","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1586\/ern.10.40","volume":"10","author":"J Avila","year":"2010","unstructured":"Avila J, Wandosell F, Hern\u00e1ndez F (2010) Role of glycogen synthase kinase-3 in Alzheimer\u2019s disease pathogenesis and glycogen synthase kinase-3 inhibitors. Expert Rev Neurother 10(5):703\u2013710","journal-title":"Expert Rev Neurother"},{"issue":"4","key":"3363_CR109","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3233\/JAD-2011-101875","volume":"24","author":"X Zhang","year":"2011","unstructured":"Zhang X, Heng X, Li T, Li L, Yang D, Zhang X et al (2011) Long-term treatment with lithium alleviates memory deficits and reduces amyloid-\u03b2 production in an aged Alzheimer\u2019s disease transgenic mouse model. J Alzheimers Dis 24(4):739\u2013749","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"3363_CR110","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/j.1399-5618.2009.00788.x","volume":"12","author":"LV Kessing","year":"2010","unstructured":"Kessing LV, Forman JL, Andersen PK (2010) Does lithium protect against dementia? Bipolar Disord 12(1):87\u201394","journal-title":"Bipolar Disord"},{"issue":"3","key":"3363_CR111","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s11596-019-2065-8","volume":"39","author":"Q Huang","year":"2019","unstructured":"Huang Q, Luo D, Chen L, Liang F-X, Chen R (2019) Effectiveness of acupuncture for Alzheimer\u2019s disease: An updated systematic review and meta-analysis. Curr Med Sci 39(3):500\u2013511","journal-title":"Curr Med Sci"},{"issue":"1","key":"3363_CR112","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13020-020-00359-1","volume":"15","author":"Z Fang","year":"2020","unstructured":"Fang Z, Tang Y, Ying J, Tang C, Wang Q (2020) Traditional Chinese medicine for anti-Alzheimer\u2019s disease: berberine and evodiamine from Evodia rutaecarpa. Chin Med 15(1):82","journal-title":"Chin Med"},{"issue":"17","key":"3363_CR113","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.3390\/ijms20174272","volume":"20","author":"V Vasic","year":"2019","unstructured":"Vasic V, Barth K, Schmidt MHH (2019) Neurodegeneration and neuro-regeneration\u2014Alzheimer\u2019s disease and stem cell therapy. Int J Mol Sci 20(17):4272","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3363_CR114","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s11033-018-4499-7","volume":"46","author":"M Alipour","year":"2019","unstructured":"Alipour M, Nabavi SM, Arab L, Vosough M, Pakdaman H, Ehsani E et al (2019) Stem cell therapy in Alzheimer\u2019s disease: possible benefits and limiting drawbacks. Mol Biol Rep 46(1):1425\u20131446","journal-title":"Mol Biol Rep"},{"issue":"1","key":"3363_CR115","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/jgs.15069","volume":"66","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Ashoor HM, Soobiah C, Rios P, Veroniki AA, Hamid JS et al (2018) Comparative effectiveness and safety of cognitive enhancers for treating Alzheimer\u2019s disease: systematic review and network metaanalysis. J Am Geriatr Soc 66(1):170\u2013178","journal-title":"J Am Geriatr Soc"},{"key":"3363_CR116","doi-asserted-by":"crossref","unstructured":"Matthews D, Ritter A, Thomas R, Andrews R, Lukic A, Revta C et al (2017) Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia. Alzheimers Dement Transl Res Clin Interv 7","DOI":"10.1002\/trc2.12106"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03363-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-022-03363-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03363-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,29]],"date-time":"2024-09-29T21:54:05Z","timestamp":1727646845000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-022-03363-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,26]]},"references-count":116,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["3363"],"URL":"https:\/\/doi.org\/10.1007\/s00228-022-03363-6","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,26]]},"assertion":[{"value":"2 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics committee of Tabriz University of Medical Science reviewed and approved the study protocol, according to the Declaration of Helsinki (Ethics code: IR.TBZMED.VCR.REC.1400.313).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent, human rights, consent to publication"}},{"value":"None declared.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}